US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type (SPECT, PET); PET Product (F-18, C11, GA 68 PSMA)
US prostate cancer nuclear medicine diagnostics market was valued at US$ 194.47 million in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach US$ 431.76 million by 2027.
Prostate cancer is affecting the prostate glands in the male. Prostate cancer is a common cancer following skin cancer in the male. Some common determinants responsible for the start of prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and also treat prostate cancer and helps radiologists to conclude the stage of cancer. US prostate cancer nuclear medicine diagnostics market is driven by factors such as the rising prevalence of prostate cancer, and the growth of innovative radiopharmaceuticals plays a vital role in the growth of the radiopharmaceuticals market. However, strict guidelines for storage, production, & use of radiopharmaceuticals is likely to obstruct the growth of the US prostate cancer nuclear medicine diagnostics market during the forecast period.
US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2027 (Mn)
Get more information on this report :
Market Insights
Rising Prevalence of Prostate Cancer
Prostate cancer (PCa) is the fourth common cancer across the US in terms of occurrence. The rising prevalence of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. For instance, according to GLOBOCAN, in 2018, there were around 2,129,118 cases of cancer in the US. Among these cases, about 10% were prostate cancer, i.e., 212,783 incidences in 2018. Moreover, the country reported 28,705 deaths due to cancer. The organization has estimated the cases of prostate cancer to reach above 737,463 in the next five years. After skin cancer, prostate cancer is the most common cancer in the American male. As per the data of the American Cancer Society, 2020, it was estimated that prostate cancer would be around 191,930 and approximately 33,330 deaths from prostate cancer in the United States for 2020. Prostate cancer is more likely to grow in older adults. Almost 6 cases in 10 are identified in men who are 65 or more. The average age at identification is around 66 in men in the US. Prostate cancer needs to be examined before the additional treatment begins. And the nuclear medicines are adopted for the diagnosis and analysis ideas. Nuclear medicines in PET and SPECT are accepted for therapeutic and diagnostic prospects. Thus, owing to the rising incidences of prostate cancer poses numerous possibilities for prostate cancer nuclear medicine diagnostics market to increase throughout the forecasted period.
Type Insights
Based on type, the US prostate cancer nuclear medicine diagnostics market is segmented into PET and SPECT. The PET segment held the largest share of the market in 2019 due to higher image quality and sophisticated reimbursement for the procedures as compared to the conventional SPECT nuclear medicine diagnostic processes. Radioisotopes used with PET prostate cancer diagnosis are Fluorine-18, Gallium-68, copper-64, zirconium-89, and Choline-11. Furthermore, the same segment is estimated to register the highest CAGR in the market during the forecast period.
PET Product Insights
The US prostate cancer nuclear medicine diagnostics market, by PET product, is segmented into F-18, C-11, and Ga68-PSMA. The F-18 segment held the largest share of the market in 2019. However, Ga68-PSMA is estimated to register the highest CAGR in the market during the forecast period due to factors such as the rising prevalence of prostate cancer, technological improvements in diagnosis systems using Ga68-PSMA, and its higher sensitivity and accuracy.
Strategic Insights
Product launches and FDA approvals strategy is commonly adopted by companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.
The market players operating in the US prostate cancer nuclear medicine diagnostics market adopt the strategy of collaborations to enlarge customer base across the world, which also permits the players to maintain their brand name.
US Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
- PET
- SPECT
US Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
- F-18
- C-11
- Ga68-PSMA
Company Profiles
- Blue Earth Diagnostics Limited
- Progenics Pharmaceuticals, Inc.
- CURIUM
- Telix Pharmaceuticals Ltd.
- NCM-USA LLC
- ABX Advanced Biochemical Compounds GmbH
- Jubilant Radiopharma
- Lantheus Medical Imaging, Inc.
- Advanced Accelerator Applications (Novartis AG)
- Theragnostics
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 US Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
1.3.2 US Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. US Prostate Cancer Nuclear Medicine Diagnostics Market Landscape
4.1 Market Overview
4.2 PEST Analysis
4.2.1 US: PEST Analysis
4.3 Expert Opinion
5. US Prostate Cancer Nuclear Medicine Diagnostics Market Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Prostate Cancer
5.1.2 Growth Of Innovative Radiopharmaceuticals
5.2 Key Market Restraints
5.2.1 Strict Guidelines for Storage, Production, & Use of Radiopharmaceuticals
5.3 Key Market Opportunities
5.3.1 Rising Demand For Precise Diagnostic Methods
5.4 CURRENT TREND
5.4.1 Use of Hybrid Nuclear Medicine For Treatment
5.5 Impact analysis
6. Prostate Cancer Nuclear Medicine Diagnostics – US Market Analysis
6.1 US Prostate Cancer Nuclear Medicine Diagnostics Market Overview
6.2 Market Positioning of Key Players
7. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type
7.1 Overview
7.2 US Prostate Cancer Nuclear Medicine Diagnostics Market, By Type (2019 and 2027)
7.2.1.1 US Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2027 (USD Million)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
8. US Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product
8.1 Overview
8.2 US Prostate Cancer Nuclear Medicine Diagnostics Market, By Product (2019 and 2027)
8.2.1.1 US Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2027 (USD Million)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
8.5 Ga68-PSMA
8.5.1 Overview
8.5.2 Ga68-PSMA: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
9. US Prostate Cancer Nuclear Medicine Diagnostics Market Industry Landscape
9.1 Overview
9.2 Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market, 2017-2020
9.3 Inorganic Growth Strategies
9.3.1 Overview
9.4 Organic Growth Strategies
9.4.1 Overview
10. COMPANY PROFILES
10.1 Blue Earth Diagnostics Limited
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Progenics Pharmaceuticals, Inc.
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Curium
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Telix Pharmaceuticals Ltd.
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 NCM-USA LLC
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 ABX advanced biochemical compounds GmbH
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Jubilant Radiopharma
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Lantheus Medical Imaging, Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Advanced Accelerator Applications (Novartis AG)
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Theragnostics
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Word Index
LIST OF TABLES
Table 1. US Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2027 (USD Million)
Table 2. US Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2027 (USD Million)
Table 3. Recent Inorganic Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market
Table 4. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics market
Table 5. List of Abbreviation
LIST OF FIGURES
Figure 1. US Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. US Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 3. PET is Expected to Show Remarkable Growth During Forecast Period
Figure 4. Ga68-PSMA is Expected to Have Fastest Growth During Forecast Period
Figure 5. Prostate Cancer Nuclear Medicine Diagnostics Market, Industry Landscape
Figure 6. US: PEST Analysis
Figure 7. Expert Opinion
Figure 8. US Prostate Cancer Nuclear Medicine Diagnostics Market – Impact Analysis of Drivers and Restraints
Figure 9. Overview of US Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 10. Market Positioning Of Key Players In US Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 11. US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Share, by Type (2019 and 2027)
Figure 12. SPECT: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
Figure 13. PET: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
Figure 14. US Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Share, by Product (2019 and 2027)
Figure 15. F-18: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
Figure 16. C-11: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
Figure 17. Ga68-PSMA: US Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue, and Forecast to 2027 (US$ Million)
Figure 18. Growth Strategies In The Prostate Cancer Nuclear Medicine Diagnostics Market, 2017-2020
The List of Companies - US Prostate Cancer Nuclear Medicine Market
- Blue Earth Diagnostics Limited
- Progenics Pharmaceuticals, Inc.
- CURIUM
- Telix Pharmaceuticals Ltd.
- NCM-USA LLC
- ABX Advanced Biochemical Compounds GmbH
- Jubilant Radiopharma
- Lantheus Medical Imaging, Inc.
- Advanced Accelerator Applications (Novartis AG)
- Theragnostics
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the prostate cancer nuclear medicine diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the US prostate cancer nuclear medicine diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.